[{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Sairiyo Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Pharmadrug Production GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Cepharanthine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH"}]